Ad5FGF-4
Phase 3- Indications
- Refractory angina, Coronary artery disease
Company intelligence / Profile preview
Gene Biotherapeutics
San Diego, California, United Statesgenebiotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 3
01
Overview
Currently conducting Phase 3 'AFFIRM' clinical study for lead product Generx (Ad5FGF-4) for treatment of refractory angina due to late-stage coronary artery disease. The therapy is designed to improve cardiac perfusion by promoting microvasculature growth in ischemic cardiac tissue.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Gene TherapyAngiogenic Gene Therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Fujifilm Diosynth Biotechnologies (manufacturing agreement for Generx)
Beyond the preview
Go deeper on Gene Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gene Biotherapeutics.